A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
Sponsor: Agios Pharmaceuticals, Inc.
Listed as NCT04770779, this observational or N/A phase trial focuses on Transfusion-dependent Alpha-Thalassemia and Transfusion-dependent Beta-Thalassemia and remains ongoing. Sponsored by Agios Pharmaceuticals, Inc., it has been updated 43 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)The mitapivat group included 171 participants. The placebo group included 87 participants.
The mitapivat group included 171 participants. The placebo group included 87 participants.
Status Flow
Change History
43 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE3 → None
-
Mar 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
▶ Show 38 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Contact Information
- Agios Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .